HGF and gastric cancer: Apicella and colleagues reported that in lung cancer and gastric cancer cells derived from patient tumors treated with tyrosine kinase inhibitors, there is an increase of glycolytic metabolism and lactate release that act as molecule driving CAFs to secrete more hepatocyte growth factor (HGF), which overcomes TKI inhibitory effects [36].